“Kimera is a deep, intimate story of me,” Luca said. “It holds a very deep meaning to follow your dreams. I think it’s the ...

Morgan Stanley (NYSE:MS) analysts adjusted their stance on Lonza Group (LONN:SW) (OTC: LZAGY), downgrading the stock from Overweight to Equalweight, while increasing the price target to CHF625 from ...

Kenosha kicked off its 175th year with a celebration recalling its unique history, trivia, quirks, resilience and renaissance ...

The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...

DelveInsight's Biologics Drug Substance Manufacturing Market Insights report provides the current and forecast market ...

Lonza Group has been a dominant player in the contract development and manufacturing space for decades. We think the outlook for Lonza looks bright, especially as drug manufacturing becomes more ...

Narrow-moat Lonza delivered solid performance in its core contract development and manufacturing organization business, but softer results from its capsules and health ingredients division ...

Lonza Group Ltd (LONN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thibault ...

For 2025, Lonza expects strong performance in its CDMO business with CER sales growth approaching 20% and CORE EBITDA margin approaching 30%. Excluding Vacaville, which is expected to contribute ...

Investing.com -- Shares of Lonza Group AG (SIX:LONN) fell more than 3% on Wednesday after the company reported full-year 2024 earnings that showed flat revenue growth and a dip in overall sales ...

Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia ...